Pantoprazole

Generic Name
Pantoprazole
Brand Names
Protonix, Somac Control, Tecta, Pantozol Control, Controloc Control
Drug Type
Small Molecule
Chemical Formula
C16H15F2N3O4S
CAS Number
102625-70-7
Unique Ingredient Identifier
D8TST4O562
Background

Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be...

Indication

Pantoprazole Injection:

Treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis
...

Associated Conditions
Erosive Esophagitis, GERD With Erosive Esophagitis, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Stress Ulcers, Zollinger-Ellison Syndrome, Conditions where a reduction of gastric acid secretion is required, Pathological hypersecretory conditions
Associated Therapies
-
Clinical Trials
Related News

Intravenous (IV) Pantoprazole in Erosive Esophagitis

Phase 4
Completed
Conditions
Esophagitis
Interventions
Drug: pantoprazole
First Posted Date
2005-08-24
Last Posted Date
2013-07-31
Lead Sponsor
Emory University
Target Recruit Count
20
Registration Number
NCT00133770
Locations
🇺🇸

Emory University School of Medicine, Atlanta, Georgia, United States

Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

Phase 3
Completed
Conditions
Peptic Ulcer Hemorrhage
First Posted Date
2002-06-28
Last Posted Date
2013-02-08
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Target Recruit Count
149
Registration Number
NCT00040495

Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

Phase 2
Completed
Conditions
Peptic Ulcer Hemorrhage
First Posted Date
2002-05-20
Last Posted Date
2013-02-08
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Target Recruit Count
12
Registration Number
NCT00037570

The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid

Phase 2
Completed
Conditions
Zollinger Ellison Syndrome
Gastrinoma
First Posted Date
1999-11-04
Last Posted Date
2017-07-02
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Registration Number
NCT00001191
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy